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Abstract
 
Lymphocytes usually differentiate into effector cells within days after antigen exposure, except
in germinal centers where terminal differentiation is delayed while somatic hypermutation cre-
ates high-affinity antibody mutants. Here we investigate whether arrest of terminal differentia-
tion can be mediated by BCL-6, a transcriptional repressor that is expressed by germinal center
B cells and is required for this phase of B cell development. We find that BCL-6 suppresses the
differentiation of transformed and primary B cells to plasma cells by inhibiting the signal trans-
ducer and activator of transcription 3–dependent expression of the major regulator of plasma
cell development, the B lymphocyte–induced maturation protein (Blimp-1). This function of
BCL-6 as a repressor of B lymphocyte differentiation may also underlie the association between
chromosomal translocations of its gene and B cell lymphomas.
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Introduction
 
In T-independent B cell responses and T-dependent B cell
responses not involving germinal centers, B cells rapidly
differentiate into plasma cells after several days of antigen-
specific clonal expansion to make antibodies available for
defense against rapidly replicating pathogens. In contrast, in
T-dependent B cell responses occuring in the germinal
center, proliferation of antigen-specific B cells persists for
weeks, suggesting that the differentiation of B cells at this
site is suppressed. Suspension of terminal differentiation of
B cells in the germinal center may be required to provide
the conditions necessary for somatic hypermutation of V
 
H
 
and V
 
L
 
 genes during repetitive cycles of proliferation, mu-
tation, cell cycle arrest, and selection of B cells having
higher affinity for antigens, the process that underlies the
phenomenon of affinity maturation of the immune re-
sponse (1, 2).
BCL-6 was initially discovered as a gene that is translo-
cated in certain non-Hodgkin’s lymphomas (3, 4). It is a se-
quence-specific transcriptional repressor that is expressed
by germinal center B cells, but not by terminally differenti-
ated plasma cells (5–7). DNA binding is mediated by six
C2H2 Krüppel-like zinc fingers and repression by a POZ
domain (8). Mice bearing homozygous disruptions of the
BCL-6 locus (9–11) have a B cell–autonomous (10) ab-
sence of T-dependent germinal center formation, but pre-
served T-independent responses. These mice also have an
inflammatory phenotype that is unrelated to the ability of
BCL-6 to regulate signal transducer and activator of tran-
scription
 
 
 
(STAT)6-dependent transcription or to its expres-
sion by lymphocytes, but may relate to the regulation of
chemokine expression in macrophages (12). A dominant
negative form of BCL-6 has been shown to arrest the
growth of a human Burkitt lymphoma and induce the ex-
pression of B lymphocyte–induced maturation protein 1
(Blimp-1), suggesting some role in regulating plasma cell
differentiation (13). However, the dominant negative
BCL-6 did not cause these cells to secrete Ig or express J
chain or syndecan 1, all markers of normal plasma cells.
Furthermore, although Blimp-1 is considered a regulator of
plasma cell differentiation (14), it is insufficient for mediat-
ing this developmental transition in all B cell lines (15), and
it has functions entirely unrelated to B cell development
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(16). Thus, a role for BCL-6 in controlling terminal B cell
maturation has not been established. In this study, we dem-
onstrate that BCL-6 suppresses cytokine-driven differentia-
tion of a B cell line and primary B cells to plasma cells by
inhibiting STAT3-dependent transcriptional events.
 
Materials and Methods
 
Retrovirus Construction and Transduction. 
 
BCL-6 cDNA was
prepared from the mouse cell line A20 by reverse transcription of
poly-A RNA and subcloned into the Moloney murine leukemia
virus–derived vector pHL6-internal ribosome entry sequence
(IRES)-green fluorescent protein (GFP) (gift of A. Venkitara-
man, Cancer Reserach Campaign, Cambridge, UK) using MluI
and BamHI sites. Serine-333 and -343 were mutated to alanine
(17) (USE Mutagenesis kit; Amersham Pharmacia Biotech).
pHL7 differs from pHL6-GFP by having a neomycin-resistance
gene in place of the GFP gene. pHL6-Blimp-1-GFP was con-
structed by subcloning the XhoI–BglII Blimp-1 fragment from
the vector pBJ1-Neo (gift of K. Calame, Columbia University,
New York, NY) into SalI–BamHI-digested pHL6-GFP. pHL6–
dominant negative STAT (DNSTAT)3-GFP was constructed by
subcloning a DNSTAT3 (18; gift of S. Akira, Osaka University,
Osaka, Japan) into the BamHI and MluI sites of pHL6-GFP. The
Phoenix packaging cell line (19) was transfected with 10–15 
 
m
 
g
of cesium-banded DNA. Supernatants were collected 48–72 h
later and filtered. Lymphocytes were plated at 3
 
 3 
 
10
 
5
 
 cells/well
of 6-well plates. Retroviral supernatants diluted 1:1 with medium
and containing 4 
 
m
 
g/ml polybrene were added to the cells, and
the plates were centrifuged for 2 h at 1,000 
 
g
 
. After an additional
6–12 h at 37
 
8
 
C, the cells were washed and fresh medium was
added.
 
Differentiation of Lymphocytes.
 
BCL1 cells, 2.5
 
 3 
 
10
 
5
 
/ml of
RPMI 1640 with 15% FCS, 10 mM Hepes, and 50 
 
m
 
M 
 
b
 
-mer-
captoethanol, were induced to differentiate by the addition of 20
ng/ml of IL-2 and 5 ng/ml of IL-5 (R&D Systems). Medium and
cytokines were replaced every 3 d, and viable cells excluding
Trypan blue were counted every 2 d. Murine splenocytes were
treated with anti-Thy1.2 and rabbit complement to yield 95%
CD19
 
1
 
 B cells. These were cultured for 48 h at 10
 
6
 
/ml in the
presence of 8 
 
m
 
g/ml of anti-CD40 (BD PharMingen), 20 ng/ml
of IL-2, 5 ng/ml of IL-4, 5 ng/ml of IL-7, and 5 ng/ml of IL-15
(R&D Systems). After retroviral transduction, the B cells were
cultured in the presence of an equivalent number of mitomycin
C–treated J558L cells expressing CD40 ligand (gift of P. Lane,
University of Birmingham, Birmingham, UK) and the cytokines,
and stained with phycoerythrin anti–syndecan 1 (BD PharMin-
gen). Alternatively, after retroviral transduction, 10
 
5
 
 GFP
 
1 
 
cells
were flow sorted (Cytomation) and then returned to culture with
2 
 
3 
 
10
 
5
 
 J558L cells and cytokines. For Western blot analyis, cells
were lysed in radioimmunoprecipitation assay (RIPA) buffer
(20), and soluble proteins were separated by electrophoresis on
8% SDS-polyacrylamide gels, transferred to nitrocellulose, and
revealed with the rabbit antibody to BCL-6 (Santa Cruz Biotech-
nology, Inc.) or Blimp-1 (gift of M. Davis, Stanford University,
Stanford, CA) and peroxidase-conjugated murine anti–rabbit
IgG. For cell cycle analysis and detection of apoptosis, BCL1 cells
were fixed in 70% ethanol, treated with RNase A (0.1 mg/ml),
and stained with propidium iodide (40 
 
m
 
g/ml). Fluorescence was
measured with a FACSort™ (Becton Dickinson). Annexin V
staining was carried out according to the manufacturer’s instruc-
tions (Oncogene Research Products).
 
J chain mRNA was detected by reverse transcriptase (RT)-
PCR (14). Blimp-1 mRNA was quantitated by real time quanti-
tative RT-PCR relative to endogenous hypoxanthine phospho-
ribosyltransferase
 
 (
 
HPRT) mRNA (21). The oligonucleotides
used for this assay were: HPRT forward, 5
 
9
 
-TTAAGCAGTA-
CAGCCCCAAAATG; HPRT reverse, 5
 
9
 
-CAAACTTGTC-
TGGAATTTCAAATCC; HPRT-Probe, 5
 
9
 
-FAM-CCTTTT-
CACCAGCAAGCTTGAAACCTTA-TAMRA; Blimp-1 for-
ward, 5
 
9
 
-GGAGGATCTGACCCGAATCA; Blimp-1 reverse,
5
 
9
 
-CTCCACCATGGAGGTCACATC; and Blimp-1 Probe, 5
 
9
 
-
FAM-AGCGACAATGCAGACCGTCTTGAGGACTAMRA.
IgM, IgG1, and IgA in culture supernatants were detected by
ELISA using rat anti–mouse isotype-specific antibodies (BD
PharMingen) as the capture antibodies and either rabbit anti–
mouse IgM-horseradish peroxidase (Sigma-Aldrich) or biotiny-
lated rat isotype-specific antibodies (BD PharMingen), followed
by streptavidin-horseradish peroxidase (Pierce Chemical Co.) as
Figure 1.  The effect of BCL-6 on the growth and viability of BCL1
cells. (a) The number of viable BCL1 cells transduced with pHL6-GFP
(s, d) or pHL6-BCL-6-GFP (h, j) was determined during culture in
medium lacking (s, h) or containing IL-2 and IL-5 (d, j). (b) Cell cy-
cle analysis of BCL1 cells cultured for 4 d in the absence or presence of
cytokines was performed by flow cytometry after staining with propidium
iodide. (c) Binding of annexin V to BCL1 cells cultured for 3 d in the ab-
sence or presence of cytokines was measured by flow cytometry. 
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the revealing antibodies. Purified antibodies (BD PharMingen)
were used to construct standard curves.
 
STAT Assays. 
 
The STAT5 site from the IL-2 receptor 
 
a
 
promoter
 
 
 
(22), which contains two STAT recognition sequences,
a dimerized STAT3 site from the 
 
a
 
2 macroglobulin promoter
(23) and a dimerized STAT6 site from the CD23 promoter (9),
were cloned upstream of pGL3-Enhancer (Promega) into which
had been previously cloned a 118-bp BamHI–NcoI fragment
from the human 
 
b
 
-globin promoter. 2
 
 3 
 
10
 
7 
 
BCL1 cells were
transfected by electroporation at 250 V, 960 
 
m
 
F (Genepulser;
Bio-Rad Laboratories) with 15 
 
m
 
g of the luciferase reporter con-
structs and 5 
 
m
 
g of a 
 
b
 
-galactosidase expression vector (Invitro-
gen). Each sample was divided into two, resuspended in medium,
and cultured for 3 h. Fresh medium, either with or without 20
 
ng/ml of IL-2 and 5 ng/ml of IL-5, was added and culture was
resumed for 24 h after which cell extracts were prepared and ana-
lyzed for protein (BCA protein assay; Pierce Chemical Co.), lu-
ciferase (Promega), and 
 
b
 
-galactosidase (Promega). For elec-
trophoretic mobility shift assays (EMSAs), 293T cells were
transfected with an expression vector bearing the full-length
wild-type mouse BCL-6 sequence, cultured for 24 h after which
nuclear extracts were prepared (24). DNA probes were end-
labeled with T4 polynucleotide kinase. The probes used were
BCL-6 consensus (25), 5
 
9
 
-GAAAATTCCTAGAAAGCATA;
STAT3 (
 
a
 
2 macroglobulin), 5
 
9
 
-CATCCTTCTGGGAATTCA-
CAT; STAT5 (IL-2 receptor 
 
a
 
), 5
 
9
 
-GTTTCTTCTAGGAAG-
TAC; and STAT6 (CD23 promoter), 5
 
9
 
-GGTGAATTTCTAA-
GAAAGG. EMSAs, cold competitor assays, and antibody-
mediated inhibition were carried out as described (26).
 
Results and Discussion
 
Inhibition by BCL-6 of Plasma Cell Differentiation of BCL1
Cells.
 
To determine whether BCL-6 can repress terminal
B cell differentiation, we studied the BCL1 CW13.20-3B3
B cell line that undergoes plasma cell differentiation in re-
sponse to IL-2 (27) and IL-5 (28). These cytokines cause
the expression of Blimp-1 (14), a regulator of terminal B
cell development that inhibits the transcription of c-myc
(29) to terminate cellular proliferation and induces the syn-
thesis of J chain and the secretion of IgM. Two BCL1 cell
lines were created by the introduction of retroviral vectors
that directed the expression of BCL-6 and GFP, or GFP
alone, followed by flow sorting. BCL-6 was detected by
Western blot analysis of lysates from cells transduced with
pHL6-BCL-6-GFP at a level slightly less than that of the
centroblast-like Ramos Burkitt lymphoma, but not in
wild-type BCL1 cells (data not shown).
IL-2 and IL-5 altered the growth of the control BCL1
line, causing cell cycle arrest at the G2/M phase and apop-
tosis (Fig. 1, a–c); these effects of the cytokines were inhib-
ited by BCL-6. IL-2 and IL-5 also caused the differentia-
tion of the control BCL1 line to a plasma cell phenotype, as
assessed by secretion of IgM, expression of J chain mRNA,
Figure 2.  The effect of BCL-6 on cytokine-induced differentiation of
BCL1 cells. (a) The secretion of IgM by BCL1 cells transduced with
pHL6-GFP (s, d) or pHL6-BCL-6-GFP (h, j) during culture in me-
dium lacking (s, h) or containing IL-2 and IL-5 (d, j) was measured
by ELISA. (b) The expression of J chain mRNA in transduced cells cul-
tured for 3 d in the absence or presence of cytokines was assessed by RT-
PCR. (c) The expression of Blimp-1 in transduced BCL1 cells cultured
for 3 d in the absence or presence of cytokines was assessed by Western
blot analysis.
Figure 3.  The effect of Blimp-1 on the growth and viability of BCL1
cells. BCL1 cells lacking (s, d) or expressing BCL-6 (h, j) were trans-
duced with pHL6-GFP (s, h) or pHL6-Blimp-1-GFP (d, j). The
fraction of viable cells that were GFP1, relative to day 2 after transduc-
tion, was determined. 
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and expression of Blimp-1 protein (Fig. 2, a–c). All three
responses were suppressed by BCL-6.
We next determined whether the ectopic expression of
Blimp-1 could overcome the capacity of BCL-6 to main-
tain the growth of BCL1 cells by constructing two addi-
tional retroviral vectors, pHL6-BCL-6-NEO and pHL6-
Blimp-1-GFP (Fig. 3). BCL1 cells were transduced with
pHL6-BCL-6-NEO and cultured in the presence of IL-2
and IL-5 to eliminate cells not expressing BCL-6. The
BCL-6
 
1
 
 cells, whose expression was confirmed by Western
blot analyis (data not shown), and wild-type BCL1 cells
were then transduced with pHL6-GFP or pHL6-Blimp-1-
GFP, and the proportion of GFP
 
1
 
 cells was assessed for 
 
.
 
2
wk. The growth of BCL1 cells expressing only GFP was
the same as nontransduced cells (Fig. 3). However, the ex-
pression of Blimp-1 caused the GFP
 
1
 
 fraction to fall, re-
gardless of the presence of BCL-6, suggesting that BCL-6
acts upstream of Blimp-1, possibly directly or indirectly
suppressing the induction of Blimp-1 by cytokines.
 
Inhibition by BCL-6 of Plasma Cell Differentiation of Pri-
mary B Cells. 
 
To examine the effect of BCL-6 on the
terminal differentiation of primary B cells, replicate samples
of in vitro–activated murine splenic B cells were transduced
with pHL6-GFP and pHL6-BCL-6-GFP, respectively.
The B cells were then cultured in the presence of CD40
ligand and IL-2, -4, -7, and -15. CD40 ligand is required
for germinal center reactions and causes B cells to become
responsive to cytokines. These particular cytokines were
chosen because, within the germinal center, IL-2 and IL-4
may be secreted by activated helper T cells at this site, and
IL-7 and IL-15 may be produced by stromal elements, such
as follicular dendritic cells. Analysis of GFP
 
1
 
 
 
cells on days 3
and 5 after transduction for the plasma cell marker, synde-
can 1, revealed lower expression among cells having BCL-6
than among the control cells (Fig. 4 a). In addition, in these
cultures containing both transduced and nontransduced B
cells, the proportion that were GFP
 
1
 
 increased among cells
expressing BCL-6, but remained the same in the control
cultures, indicating that BCL-6 does not inhibit the
growth-promoting effects of CD40 ligand and cytokines
(data not shown).
In separate experiments, transduced GFP
 
1
 
 
 
primary B
cells were flow sorted to 
 
z
 
80% purity, cultured for 5 d in
the presence of CD40 ligand and the same cytokines, and
assayed for differentiation by Ig secretion and Blimp-1 ex-
pression. The increase in Blimp-1 mRNA and in the secre-
tion of IgM, IgG1, and IgA in B cells expressing BCL-6
was reduced to 20–40% of the levels seen with the GFP
only, control cells (Fig. 4, b and c). The predominant iso-
type, regardless of the presence of BCL-6, was IgG1, pre-
sumably reflecting isotype switching induced by IL-4.
Therefore, BCL-6 can suppress terminal differentiation of
primary B cells.
 
BCL-6, STAT3, and Plasma Cell Differentiation. 
 
IL-2
and IL-5 activate STAT3 and STAT5a/b (for a review, see
reference 30), and the BCL-6 consensus DNA-binding site
is similar to that for STATs (9). However, BCL-6 has been
shown only to bind to STAT6 sites from the CD23 pro-
 
moter (9) and the germline I
 
e
 
 promoter (25). To determine
whether BCL-6 might also regulate STAT3- or STAT5-
dependent transcription, luciferase reporter constructs con-
taining a dimerized STAT3 site from the 
 
a
 
2-macroglobu-
lin promoter or a dimerized STAT5 site from the IL-2
receptor 
 
a
 
 chain promoter, were transiently expressed in
the control and BCL-6
 
1
 
 BCL1 cell lines; the cells were ac-
tivated by IL-2 and IL-5. BCL-6–inhibited cytokine in-
duced transcription from the STAT3 reporter, but not the
STAT5 reporter (Fig. 5 a). The interaction of BCL-6 with
STAT sites was further evaluated by gel mobility shift as-
says in which BCL-6 was shown to form protein–DNA
Figure 4. The effect of BCL-6 on the differentiation of primary B
cells. (a) Primary B cells transduced with pHL6-GFP or pHL6-BCL-6-
GFP were cultured in the presence of CD40 ligand and IL-2, -4, -7, and
-15, and GFP1 cells were assessed for expression of syndecan 1 by flow
cytometry. (b) The secretion of IgM, IgG1, and IgA by flow-sorted pri-
mary B cells transduced with pHL6-GFP or pHL6-BCL-6-GFP after cul-
ture for 5 d in the presence of CD40 ligand and IL-2, -4, -7, and -15 was
measured by ELISA. (c) The expression of Blimp-1 mRNA relative to
HPRT mRNA by flow-sorted primary B cells, which had been trans-
duced with pHL6-GFP or pHL6-BCL-6-GFP and cultured with CD40
ligand and IL-2, -4, -7, and -15, was determined on day 5. 
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complexes with radiolabeled STAT3 and STAT6 binding
site probes that were inhibited by antibody to BCL-6.
BCL-6 did not form a complex with the STAT5 probe
(Fig. 5 b). Furthermore, unlabeled oligonucleotides having
STAT3 or STAT6 binding sites competed with a labeled
probe having the consensus sequence recognised by BCL-6,
whereas the oligonucleotide having a STAT5 binding site
was relatively less effective (Fig. 5 c). Since IL-2 alone, but
not IL-5, can induce differentiation of BCL1 cells, and IL-2,
but not IL-5, activates STAT3, the finding that BCL-6 re-
presses STAT3-dependent transcription was consistent
with the means by which terminal differentiation of B cells
is suppressed by BCL-6.
To provide direct evidence for an essential role of
STAT3 in BCL1 differentiation, a retroviral vector was
constructed, pHL6-DNSTAT3-GFP, directing the expres-
sion of a dominant negative form of this transcription factor
(18). BCL1 cells were transduced with this or a control
vector, pHL6-GFP, and the number of viable GFP
 
1
 
 cells
was measured during culture in the absence or presence of
IL-2 and IL-5
 
. 
 
The cytokine-induced decrease in viability
observed with control cells was attenuated in cells express-
ing DNSTAT3 (Fig. 5 d). The control and DNSTAT3
BCL1 cells were isolated by cell sorting and compared with
BCL-6–expressing BCL1 cells during culture in the pres-
ence of IL-2 and IL-5 for the induction of Blimp-1 and se-
cretion of IgM. The increase in Blimp-1 mRNA, as
measured by real time quantitative RT-PCR, and IgM se-
cretion was suppressed by DNSTAT3, although not as ef-
fectively as by BCL-6 (Fig. 5, e and f). Thus, STAT3 is es-
sential for cytokine-induced terminal differentiation of B
cells, suggesting that the ability of BCL-6 to regulate
STAT3-dependent transcription is responsible for its sup-
pression of differentiation.
This study shows that a potential physiological function
for BCL-6 is the inhibition of differentiation of B cells to
plasma cells in the germinal center, allowing affinity matu-
ration of the immune response to occur. This function may
account for the inability of mice lacking BCL-6 to form
germinal centers, since in its absence, activated B cells
Figure 5.  STAT3 and regulation by
BCL-6 of the differentiation of BCL1
cells. (a) Transduced BCL1 cells were
transfected with luciferase reporter con-
structs having STAT3 or STAT5 sites,
cultured in the absence or presence of
cytokines, and assessed for luciferase ac-
tivity relative to the activity of cells
transfected with a construct lacking a
STAT site. (b) Nuclear lysates from un-
transfected (lanes 1–6) and BCL-6–trans-
fected 293T fibroblasts (lanes 7–12) were
incubated with control antiserum or
anti–BCL-6 followed by addition of 32P-
oligonucleotide probes having STAT
sites, and subjected to gel mobility shift
assay. (c) Nuclear lysates having BCL-6
were incubated with a 32P-oligonucle-
otide probe having a consensus BCL-6
binding site in the absence or presence
of 1, 5, or 50 pmol of unlabeled, com-
petitor probes having the designated
STAT sites, and subjected to gel mobil-
ity shift assay. (d) The number of viable
BCL1 cells transduced with pHL6-GFP
(s, d) or pHL6-DNSTAT3-GFP (h,
j) was measured during culture in me-
dium lacking (s, h) or containing IL-2
and IL-5 (d, j). (e) The expression of
Blimp-1 mRNA compared with HPRT
mRNA, in BCL1 cells transduced with
pHL6-GFP (d), pHL6-BCL-6-GFP
(m), or pHL6-DNSTAT3-GFP (j) was
measured by real time quantitative RT-
PCR during culture in medium contain-
ing IL-2 and IL-5, and is expressed rela-
tive to the level in pHL6-GFP BCL1
cells just before the addition of cyto-
kines. (f) The secretion of IgM by BCL1
cells transduced with pHL6-GFP (s,
d), pHL6-BCL-6-GFP (m), or pHL6-
DNSTAT3-GFP (j) during culture in
medium lacking (s) or containing IL-2
and IL-5 (d, m, j) was measured by
ELISA.1846 BCL-6 Blocks STAT3–dependent Plasma Cell Differentiation
would terminally differentiate rather than accumulate as
centrocytes and centroblasts. This effect of BCL-6 is
caused, at least in part, by the repression of STAT3 ele-
ments involved in Blimp-1 expression. One might antici-
pate that there may be other STAT3 sites which mediate
the growth-promoting function of activated STAT3 and
are not affected by BCL-6, thereby enabling this transcrip-
tional repressor to bias the cytokine response of germinal
center B cells towards growth rather than terminal differen-
tiation. Finally, this study offers an explanation for the on-
cogenic potential of BCL-6 since its constitutive expression
through chromosomal translocations would block terminal
differentiation and maintain a proliferating, mutating ger-
minal center B cell pool, thereby increasing the likelihood
of other genetic events associated with the development of
B cell lymphomas.
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